Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer
Vall d'Hebron Hospital Universitari · Vall d'Hebron Institute of Oncology · +2 more institutions
Abstract
Colorectal cancer (CRC) with mismatch-repair deficiency (dMMR) or high microsatellite instability (MSI-H) represents a distinct molecular subtype highly sensitive to immune checkpoint inhibitors (ICIs). Landmark clinical trials have established ICIs as standard-of-care in this setting, demonstrating durable responses and improved survival. However, up to one-third of patients will exhibit primary or acquired resistance, highlighting the urgent need for predictive biomarkers and novel therapeutic strategies. This review summarizes the clinical evidence supporting ICIs in dMMR/MSI-H CRC, explores mechanisms of resistance-including intrinsic and extrinsic modulators-and evaluates the role of potential predictive…
Citation impact
- FWCI
- 69.57
- Percentile
- 99%
- References
- 111
Authors
13- CSClara Salva de TorresCorresponding
Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
- EEEvelyn Elias
Icahn School of Medicine at Mount Sinai
- CVC. Vaghi
Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
- NSN. Saoudi Gonzalez
Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
- AGAriadna García
Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
Topics & keywords
- Colorectal cancer
- Microsatellite instability
- DNA mismatch repair
- Clinical trial
- Immune system
- Immune checkpoint
- Acquired resistance